Feature Updates

Preview of Clinical Results from ESMO 2024!

11 September 2024
3 min read

On September 9, 2024, the official website of the European Society for Medical Oncology (ESMO) Annual Meeting made public a batch of clinical trial results summaries. The Synapse database immediately launched a search portal for ESMO clinical results data, facilitating user access.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

On the results listing page, you can clearly see each ESMO clinical trial entry, including: ID number, title, institution, clinical registration number, clinical phase, population characteristics, clinical trial protocols, clinical results data, and clinical evaluations.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

By clicking on a specific clinical trial, you enter a detailed page where you can view comprehensive trial information, as well as endpoint indicator information. The presentation of endpoint indicators is available in two formats: tabular display and flowchart display.

图形用户界面, 应用程序, Teams

描述已自动生成

图形用户界面, 应用程序, Teams

描述已自动生成

图形用户界面, 应用程序

描述已自动生成

Obtain the ESMO clinical outcomes you want through screening

By searching for Sacituzumab Govitecan + ESMO 2024, you can obtain 2 clinical trial results.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

By searching for NSCLC + ESMO 2024, you can obtain 84 clinical trial results.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can obtain precise clinical outcomes by setting up more advanced filtering combinations based on your focus areas.

How to Easily View the Clinical Results Using Synapse Database?

If you want to know the other clinical results of popular conferences, please lick on the “Clinical Results” on the homepage of Patsnap Synapse, which provides multi-dimensional screening and filtering of drugs, indications, targets, companies, result evaluation, release date, popular conferences, etc. to help you quickly locate the data you need. 

Select the clinical meeting you are interested in, such as ESMO. In the results, you can quickly locate the data you want to view by indication, phase and drug name. 

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

A single result clearly shows important information such as registration number, phase, indication, Sponsor/Collaborator, biomarker, Trial number, dosing regimen and more. 

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

If you would like to view more information about this result, you can go to the result detail page by clicking on the title. 

Above the headings, we provide the original source of the outcome data. The basic information is supplemented with more information beyond the list, such as company, study. design, etc. 

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

In the important Outcome Measures section, we provide both list and flowchart forms, which are convenient for you to overview the comparison group information and core indicator data. 

图形用户界面, 应用程序, Teams

描述已自动生成

图示

中度可信度描述已自动生成

Finally, if you need to download these results, you can conveniently check the check boxes on the left side of the list, or directly click the "Export" button to download the data for personalized analysis and file sharing.

Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

IDeate-Lung01 Phase 2 Trial: Promising Response Rates with Ifinatamab Deruxtecan in Advanced Small Cell Lung Cancer
Latest Hotspot
3 min read
IDeate-Lung01 Phase 2 Trial: Promising Response Rates with Ifinatamab Deruxtecan in Advanced Small Cell Lung Cancer
11 September 2024
The IDeate-Lung01 Phase 2 Trial shows Ifinatamab Deruxtecan maintains encouraging objective response rates in patients with advanced-stage small cell lung cancer.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Sep 11
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Sep 11
11 September 2024
Sep 11th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
GSK reports promising phase III trial outcomes for Nucala (mepolizumab) in treating COPD
Latest Hotspot
3 min read
GSK reports promising phase III trial outcomes for Nucala (mepolizumab) in treating COPD
10 September 2024
GSK plc (LSE/NYSE: GSK) released encouraging top-line outcomes from MATINEE in adult patients suffering from chronic obstructive pulmonary disease (COPD).
Read →
Hengrui's JAK1 Inhibitor Ivarmacitinib Receives Approval for New Indication Application
Hot Spotlight
6 min read
Hengrui's JAK1 Inhibitor Ivarmacitinib Receives Approval for New Indication Application
10 September 2024
Competing in the $40 Billion Alopecia Areata Market: Hengrui's JAK1 Inhibitor Ivarmacitinib Receives Approval for New Indication Application.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.